HIV-1 Tropism Testing in Subjects Achieving Undetectable HIV-1 RNA : Diagnostic Accuracy, Viral Evolution and Compartmentalization
Pou, Christian (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Codoñer, Francisco M. (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Thielen, Alexander (Max-Planck-Institut für Informatik, Saarbücken, Germany)
Bellido, Rocío (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Pérez-Álvarez, Susana (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Cabrera Navarro, Cecilia (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Dalmau, Judith (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Curriu Martí, Marta (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Lie, Yolanda (Monogram Biosciences Inc., South San Francisco, California, United States of America)
Noguera-Julian, Marc (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Puig, Jordi (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida)
Martínez-Picado, Javier (Institució Catalana de Recerca i Estudis Avançats)
Blanco, Julià (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Coakley, Eoin (Monogram Biosciences Inc., South San Francisco, California, United States of America)
Däumer, Martin (Institut für Immunologie und Genetik, Kaiserlautern, Germany)
Clotet Sala, Bonaventura (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida)
Paredes, Roger (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida)
Universitat Autònoma de Barcelona

Data:	2013
Resum:	Technically, HIV-1 tropism can be evaluated in plasma or peripheral blood mononuclear cells (PBMCs). However, only tropism testing of plasma HIV-1 has been validated as a tool to predict virological response to CCR5 antagonists in clinical trials. The preferable tropism testing strategy in subjects with undetectable HIV-1 viremia, in whom plasma tropism testing is not feasible, remains uncertain. We designed a proof-of-concept study including 30 chronically HIV-1-infected individuals who achieved HIV-1 RNA <50 copies/mL during at least 2 years after first-line ART initiation. First, we determined the diagnostic accuracy of 454 and population sequencing of gp120 V3-loops in plasma and PBMCs, as well as of MT-2 assays before ART initiation. The Enhanced Sensitivity Trofile Assay (ESTA) was used as the technical reference standard. 454 sequencing of plasma viruses provided the highest agreement with ESTA. The accuracy of 454 sequencing decreased in PBMCs due to reduced specificity. Population sequencing in plasma and PBMCs was slightly less accurate than plasma 454 sequencing, being less sensitive but more specific. MT-2 assays had low sensitivity but 100% specificity. Then, we used optimized 454 sequence data to investigate viral evolution in PBMCs during viremia suppression and only found evolution of R5 viruses in one subject. No de novo CXCR4-using HIV-1 production was observed over time. Finally, Slatkin-Maddison tests suggested that plasma and cell-associated V3 forms were sometimes compartmentalized. The absence of tropism shifts during viremia suppression suggests that, when available, testing of stored plasma samples is generally safe and informative, provided that HIV-1 suppression is maintained. Tropism testing in PBMCs may not necessarily produce equivalent biological results to plasma, because the structure of viral populations and the diagnostic performance of tropism assays may sometimes vary between compartments. Thereby, proviral DNA tropism testing should be specifically validated in clinical trials before it can be applied to routine clinical decision-making.
Ajuts:	Ministerio de Sanidad y Consumo RD06/0006 European Commission 238885
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Publicat a:	PloS one, Vol. 8 (august 2013) , ISSN 1932-6203

DOI: 10.1371/journal.pone.0067085
PMID: 23936293

12 p, 630.4 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles de recerca
Articles > Articles publicats